A Cozzi-Lepri

Summary

Affiliation: University College London
Country: UK

Publications

  1. ncbi Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy
    Alessandro Cozzi-Lepri
    Royal Free and University College Medical School, London, UK
    Antivir Ther 10:791-802. 2005
  2. ncbi Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen
    Alessandro Cozzi-Lepri
    Royal Free and University College Medical School, London, UK
    AIDS 21:721-32. 2007
  3. ncbi A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads
    Alessandro Cozzi-Lepri
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, University College London, United Kingdom
    J Infect Dis 194:20-8. 2006
  4. ncbi Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study
    Alessandro Cozzi-Lepri
    Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK
    J Infect Dis 185:1062-9. 2002
  5. doi Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study
    Alessandro Cozzi-Lepri
    Research Department of Infection and Population Health, Royal Free and University College Medical School, London, UK
    AIDS 22:2187-98. 2008
  6. doi Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response
    A Cozzi-Lepri
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, University College London, London, UK
    HIV Med 9:27-40. 2008
  7. doi Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings
    Alessandro Cozzi-Lepri
    Research Department of Infection and Population Health, Royal Free and University College Medical School, London, United Kingdom
    J Infect Dis 200:687-97. 2009
  8. doi Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients
    Amanda Mocroft
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, Division of Population Health, University College London Medical School, Royal Free Campus, London, UK
    AIDS 24:1667-78. 2010
  9. doi A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study
    J Reekie
    Research Department of Infection and Population Health, University College London Medical School, Royal Free Campus, London, UK
    HIV Med 12:259-68. 2011
  10. pmc Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study
    Rebecca K Lodwick
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, UCL Medical School, Royal Free Campus, London, UK
    Lancet 376:340-5. 2010

Detail Information

Publications53

  1. ncbi Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy
    Alessandro Cozzi-Lepri
    Royal Free and University College Medical School, London, UK
    Antivir Ther 10:791-802. 2005
    ....
  2. ncbi Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen
    Alessandro Cozzi-Lepri
    Royal Free and University College Medical School, London, UK
    AIDS 21:721-32. 2007
    ..To estimate the extent of drug resistance accumulation in patients kept on a virologically failing regimen and its determinants in the clinical setting...
  3. ncbi A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads
    Alessandro Cozzi-Lepri
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, University College London, United Kingdom
    J Infect Dis 194:20-8. 2006
    ....
  4. ncbi Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study
    Alessandro Cozzi-Lepri
    Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK
    J Infect Dis 185:1062-9. 2002
    ..The findings of this study are in agreement with those of other observational studies...
  5. doi Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study
    Alessandro Cozzi-Lepri
    Research Department of Infection and Population Health, Royal Free and University College Medical School, London, UK
    AIDS 22:2187-98. 2008
    ..To investigate the relationship between detection of HIV drug resistance by 2 years from starting antiretroviral therapy and the subsequent risk of progression to AIDS and death...
  6. doi Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response
    A Cozzi-Lepri
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, University College London, London, UK
    HIV Med 9:27-40. 2008
    ..To investigate the concordance between any of the results of nine HIV-1 drug-resistance interpretation systems (ISs) and their ability to predict week 8 and week 24 virological responses to abacavir-containing combination therapy...
  7. doi Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings
    Alessandro Cozzi-Lepri
    Research Department of Infection and Population Health, Royal Free and University College Medical School, London, United Kingdom
    J Infect Dis 200:687-97. 2009
    ....
  8. doi Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients
    Amanda Mocroft
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, Division of Population Health, University College London Medical School, Royal Free Campus, London, UK
    AIDS 24:1667-78. 2010
    ..Chronic kidney disease (CKD) in HIV-positive persons might be caused by both HIV and traditional or non-HIV-related factors. Our objective was to investigate long-term exposure to specific antiretroviral drugs and CKD...
  9. doi A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study
    J Reekie
    Research Department of Infection and Population Health, University College London Medical School, Royal Free Campus, London, UK
    HIV Med 12:259-68. 2011
    ..The aim of this analysis was to compare the durability of nevirapine, efavirenz and lopinavir regimens based on these measures...
  10. pmc Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study
    Rebecca K Lodwick
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, UCL Medical School, Royal Free Campus, London, UK
    Lancet 376:340-5. 2010
    ..We aimed to examine this by analysis of pooled data from industrialised countries...
  11. doi The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*
    A Cozzi-Lepri
    Department of Infection and Population Health, Division of Population Health, University College London, London, UK
    HIV Med 13:62-72. 2012
    ..How quickly NNRTI resistance accumulates in patients with a delayed switch from nevirapine or efavirenz despite virological failure, when these drugs are used as a component of combination antiretroviral therapy (cART), remains unclear...
  12. doi Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study
    Wendy P Bannister
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
    J Acquir Immune Defic Syndr 48:324-33. 2008
    ..To investigate prevalence of transmitted drug-resistant human immunodeficiency virus (TDR) and factors associated with TDR and to compare virological and CD4 count response to combination antiretroviral therapy...
  13. doi Serious fatal and nonfatal non-AIDS-defining illnesses in Europe
    Amanda Mocroft
    Research Department of Infection and Population Health, University College Medical School, London, UK
    J Acquir Immune Defic Syndr 55:262-70. 2010
    ..Little is known about the incidence and risk factors for serious non-AIDS-defining events...
  14. doi Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy
    Wendy P Bannister
    Research Department of Infection and Population Health, University College London Medical School, London, UK
    J Antimicrob Chemother 66:901-11. 2011
    ....
  15. doi History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change
    J Reekie
    Research Department of Infection and Population Health, University College London Medical School, UK
    HIV Med 11:469-78. 2010
    ..The relationship between such differences and risk of virological failure after starting a new antiretroviral could help with patient monitoring strategies...
  16. ncbi Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals
    A N Phillips
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 15:2379-84. 2001
    ..The major challenge is to develop regimens that can be taken consistently and safely for such long periods of time...
  17. doi Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA
    Wendy P Bannister
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 22:367-76. 2008
    ..To compare virological outcome and genotypic resistance profiles in HIV-1-infected patients starting non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing regimens...
  18. ncbi Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?
    Antonia L Moore
    Department of Primary Care and Population Sciences and Centre for HIV Medicine, Royal Free and University College School of Medicine, Hampstead, London NW3 2PF, UK
    AIDS 16:615-8. 2002
    ....
  19. doi Loss to follow-up in an international, multicentre observational study
    A Mocroft
    Royal Free and University College Medical School, London, UK
    HIV Med 9:261-9. 2008
    ..The aim of this work was to assess loss to follow-up (LTFU) in EuroSIDA, an international multicentre observational cohort study...
  20. doi Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?
    Joanne Reekie
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, Royal Free and University College Medical School, London, UK
    AIDS 22:2381-90. 2008
    ..To investigate whether HIV-infected patients on a stable and fully suppressive combination antiretroviral therapy (cART) regimen could safely be monitored less often than the current recommendations of every 3 months...
  21. ncbi When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study
    A Cozzi Lepri
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, London, UK
    AIDS 15:983-90. 2001
    ..The increase in CD4 cells restored by HAART is meaningful in that they are associated with reduced risk of disease/death...
  22. ncbi The changing demographics of new HIV diagnoses at a London centre from 1994 to 2000
    S M Barry
    Department of Thoracic and HIV Medicine, Royal Free Centre for HIV Medicine, London, UK
    HIV Med 3:129-34. 2002
    ..To document the demographic changes in new HIV diagnoses at the Royal Free Hospital, London, UK, between 1994 and 2000...
  23. doi Durability of FTC/TDF-containing cART regimens in a large cohort of HIV-infected patients seen for care in Italy
    A Cozzi-Lepri
    University College London, Infection and Population Health, London, UK
    J Int AIDS Soc 15:18135. 2012
    ..17 for TVD/EFV and 5.3 for Atripla (adjusted RR vs. TVD/PIr=0.51, 95% CI: 0.19-1.34). Durability of Atripla was comparable to that of TVD/EFV and potentially longer than that of TVD/PIr. Unmeasured confounding cannot be ruled out...
  24. ncbi Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals
    Giorgio Antonucci
    National Institute of Infectious Diseases, L Spallanzani, Roma, Italy
    Antivir Ther 10:109-17. 2005
    ..These results suggest that GBV-C coinfection may play a role in determining the rate of HIV rebound possibly by competing with HIV replication after HIV load has been successfully suppressed by HAART...
  25. pmc A whole-genome association study of major determinants for host control of HIV-1
    Jacques Fellay
    Center for Population Genomics and Pharmacogenetics, Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC 27710, USA
    Science 317:944-7. 2007
    ..These findings emphasize the importance of studying human genetic variation as a guide to combating infectious agents...
  26. ncbi Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response
    Koen Deforche
    Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium
    Antivir Ther 13:399-407. 2008
    ..A method has been developed to estimate a fitness landscape experienced by HIV-1 under treatment selective pressure as a function of the genotypic sequence thereby also estimating the genetic barrier to resistance...
  27. ncbi Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
    J Infect Dis 196:1180-90. 2007
    ..A negative association between the polymorphism F214L and type 1 thymidine analogue (TA) mutations (TAMs) has been observed. However, the virological response to TAs according to the detection of F214L has not been evaluated...
  28. doi Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response
    Lambert Assoumou
    Institut National de la Sante et de la Recherche Medicale, U720, Paris, France
    J Infect Dis 198:470-80. 2008
    ..This study was performed to investigate the concordance between commonly used human immunodeficiency virus type 1 (HIV-1) drug resistance interpretation systems for didanosine (ddI) and their ability to predict responses at weeks 8 and 24...
  29. ncbi Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy
    Gilbert Greub
    University Hospital, Lausanne, Switzerland
    AIDS 16:1967-9. 2002
  30. doi Self-reported sexual dysfunction is frequent among HIV-infected persons and is associated with suboptimal adherence to antiretrovirals
    Maria Paola Trotta
    Istituto Nazionale per le Malattie Infettive, L Spallanzani IRCCS, Rome, Italy
    AIDS Patient Care STDS 22:291-9. 2008
    ..44; 95% CI 1.30-9.08). In conclusion, patients' perceived SD represents a relevant problem for HIV-infected persons treated with antiretrovirals and is strongly associated with suboptimal HAART adherence...
  31. ncbi Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?
    Paola Cicconi
    Clinic of Infectious Diseases and Tropical Medicine University of Milan, Milan, Italy
    AIDS 21:599-606. 2007
    ..To investigate if the risk of liver enzyme elevation (LEE) in HIV/hepatitis B or C (HBV, HCV) co-infection is altered by HAART (two or more drugs)...
  32. ncbi Significant link between sCD30 changes and HIV viremia in patients treated with HAART
    Priscilla Biswas
    Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Med Virol 78:1513-9. 2006
    ..The change in sCD30 levels from pre-therapy to the date of first viral suppression could be used to identify patients who are more likely to experience later virological rebound among those who achieve initially virological success...
  33. ncbi Prevalence of HIV-1 primary drug resistance in seroconverters of the ICoNA cohort over the period 1996-2001
    Michela Violin
    J Acquir Immune Defic Syndr 36:761-4. 2004
  34. ncbi Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed
    Carlo Federico Perno
    Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, University of Rome Tor Vergata, Italy
    J Infect Dis 189:1983-7. 2004
    ..5 [95% confidence interval, 1.89-95.6]; P=.009) and, possibly, of 10I/V. This suggests a potential role for the presence of 36I at baseline in predicting the appearance of 90M at virological failure...
  35. ncbi Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART
    Andrea Antinori
    Istituto Nazionale per le Malattie Infettive, L Spallanzani IRCCS, Roma, Italy
    Antivir Ther 9:291-6. 2004
    ..6%) experienced virological rebound by 96 weeks. Both self-reported non-adherence and sub-optimal concentration were independently associated with a higher risk of virological rebound...
  36. ncbi Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy
    Michela Violin
    Institute of Infectious and Tropical Diseases, University of Milan, Italy
    AIDS 18:227-35. 2004
    ..To investigate the impact of 215 HIV-1 revertants on the risk of virological failure of the first thymidine analog-containing highly active antiretroviral therapy (HAART)...
  37. ncbi Changes in viral load in people with virological failure who remain on the same HAART regimen
    Alessandro Cozzi-Lepri
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, London, UK
    Antivir Ther 8:127-36. 2003
    ..To assess the rate of change in viral load and CD4 count over time in HIV-infected patients experiencing virological failure on a HAART regimen...
  38. ncbi Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens
    Maria Paola Trotta
    Istituto Nazionale per le Malattie Infettive, L Spallanzani IRCCS, Rome, Italy
    AIDS 17:1099-102. 2003
    ..By contrast, younger age, self-report of active drug use, fatigue or vomiting negatively affected adherence. Self-reported sexual dysfunction was significantly associated with non-adherence only in PI-treated individuals...
  39. ncbi Relationship between HAART adherence and adipose tissue alterations
    Adriana Ammassari
    Clinica delle Malattie Infettive, Universita Cattolica del S Cuore, Roma, Italy
    J Acquir Immune Defic Syndr 31:S140-4. 2002
    ..Better adherence is associated with a higher risk of subsequent occurrence of ATA, while patient-perceived onset of morphologic alterations can reduce adherence to antiretroviral therapy...
  40. ncbi Virologic correlates of adherence to antiretroviral medications and therapeutic failure
    Carlo Federico Perno
    INMI L Spallanzani, Rome, Italy
    J Acquir Immune Defic Syndr 31:S118-22. 2002
    ....
  41. ncbi Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study
    Massimo Galli
    Institute of Infectious Diseases and Tropical Medicine, University of Milan, L Sacco Hospital, Via G B Grassi, 74 20157 Milan, Italy
    Arch Intern Med 162:2621-8. 2002
    ..Adipose tissue alterations (ATAs) are a frequent untoward effect of antiretroviral therapy, the causes of which remain incompletely explained...
  42. ncbi Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 9:743-52. 2004
    ..This work was presented in part at the First European Workshop on HIV Drug Resistance. Luxembourg, 4-6 March 2003 (Abstract 44); and at the 9th European Conference on CIinical AIDS Therapy. Warsaw, 25-28 October 2003 (Abstract F6/7)...
  43. ncbi Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study
    Cecilia Cabrera
    IrsiCaixa Foundation and Lluita contra la SIDA Foundation, Badalona, Spain
    Antivir Ther 9:787-800. 2004
    ....
  44. ncbi Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    Antivir Ther 11:609-18. 2006
    ..A multi-cohort prospective observational comparative study was performed...
  45. ncbi Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis
    Massimo Puoti
    Clinica di Malattie Infettive e Tropical, Universita degli Studi di Brescia, Brescia, Italy
    Antivir Ther 11:567-74. 2006
    ..The impact of lamivudine (3TC) as part of combination antiretroviral therapy (cART) on the risk of liver-related death (LRD) in HIV/hepatitis B virus (HBV)-coinfected patients has not been extensively studied...
  46. ncbi Evolution of HVR-1 quasispecies after 1-year treatment in HIV/HCV-coinfected patients according to the pattern of response to highly active antiretroviral therapy
    Mariacarmela Solmone
    National Institute of Infectious Diseases L Spallanzani, Rome
    Antivir Ther 11:87-94. 2006
    ..On the whole, these findings suggest that, in patients undergoing HAART, the extent of HCV variability and the evolution of HVR-1 quasispecies is influenced by the pattern of response to antiretroviral therapy...
  47. ncbi Effect of hepatitis C virus genotype on CD4+ T cell count in a cohort of antiretroviral-naive HIV-1-infected individuals
    Giorgio Antonucci
    J Infect Dis 192:703-4; author reply 704-5. 2005
  48. ncbi Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals
    Giorgio Antonucci
    National Institute of Infectious Diseases, L Spallanzani, Rome, Italy
    Clin Infect Dis 40:e101-9. 2005
    ..We also aimed to assess whether the response to HAART in these patients varied according to HCV genotype...
  49. ncbi Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian Cohort of Antiretroviral-Naive Patients
    Antonella d'Arminio Monforte
    Istituto di Malattie Infettive e Tropicali, Universita di Milano, Milano, Italy
    J Acquir Immune Defic Syndr 38:407-16. 2005
    ....
  50. ncbi CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l
    Cristina Mussini
    Clinic of Infectious and Tropical Diseases, Azienda Ospedaliero Universitaria Policlinico, University of Modena and Reggio Emilia, Via del Pozzo, 71, 41100 Modena, Italy
    AIDS 19:287-94. 2005
    ..Little is known about CD4 cell count changes in patients with high CD4 cell counts who interrupt antiretroviral therapy, especially in those with a nadir of 250-350 x 10 cells/l...
  51. ncbi The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug?
    Massimo Puoti
    Institute of Infectious and Tropical Diseases, Spedali Civili, University of Brescia, Brescia, Italy
    Antivir Ther 9:811-7. 2004
    ..3; -131.7, P=0.003] and a significantly reduced risk of liver-related morbidity/mortality [Relative hazard (RH)=0.07; 95% CI: 0.01-0.38, P=0.002] than those starting a lamivudine sparing-regimen...
  52. ncbi Low prevalence of primary mutations associated with drug resistance in antiviral-naive patients at therapy initiation
    Carlo Federico Perno
    IRCCS L Spallanzani Hospital, Via Portuense 292, 00149 Rome, Italy
    AIDS 16:619-24. 2002
    ..To assess the prevalence of mutations in the reverse-transcriptase (RT) and protease (PR) region in a cohort of chronically-infected HIV-positive patients requiring highly active antiretroviral therapy (HAART)...
  53. ncbi Multiple viral infections
    Giovanni B Gaeta
    Department of Infectious Diseases, Viral Hepatitis Unit, Second University of Naples, Naples 80135, Italy
    J Hepatol 44:S108-13. 2006
    ..Studies are needed to assess treatment strategies...